Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Anaptysbio Inc (ANAB)

Anaptysbio Inc (ANAB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 578,659
  • Shares Outstanding, K 28,186
  • Annual Sales, $ 63,180 K
  • Annual Income, $ -57,800 K
  • 60-Month Beta 0.17
  • Price/Sales 9.32
  • Price/Cash Flow N/A
  • Price/Book 1.75
Trade ANAB with:

Options Overview Details

View History
  • Implied Volatility 118.74% ( +5.91%)
  • Historical Volatility 59.27%
  • IV Percentile 100%
  • IV Rank 100.00%
  • IV High 118.74% on 05/25/22
  • IV Low 63.07% on 12/23/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 4
  • Volume Avg (30-Day) 439
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 1,787
  • Open Int (30-Day) 1,494

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.95
  • Number of Estimates 4
  • High Estimate -0.59
  • Low Estimate -1.17
  • Prior Year -0.02
  • Growth Rate Est. (year over year) -4,650.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.97 +1.16%
on 05/25/22
24.91 -22.96%
on 05/03/22
-4.29 (-18.27%)
since 04/25/22
3-Month
18.97 +1.16%
on 05/25/22
31.54 -39.16%
on 02/28/22
-12.24 (-38.94%)
since 02/25/22
52-Week
18.97 +1.16%
on 05/25/22
37.89 -49.35%
on 11/08/21
-4.81 (-20.04%)
since 05/25/21

Most Recent Stories

More News
AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Lags Revenue Estimates

AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -50.57% and 87.99%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

ANAB : 19.19 (-3.95%)
ABUS : 2.25 (+2.74%)
AnaptysBio Announces First Quarter 2022 Financial Results and Provides Pipeline Update

Top-line data from the ongoing imsidolimab (anti-IL-36R Ab) HARP Phase 2 trial in moderate-to-severe hidradenitis suppurativa is anticipated in Q3...

ANAB : 19.19 (-3.95%)
AnaptysBio Announces Positive ANB032 (anti-BTLA agonist) Top-Line Phase 1 Data and Provides Pipeline Updates

ANB032, our wholly owned anti-BTLA agonist antibody, demonstrated favorable safety, tolerability and a rapid and sustained pharmacokinetic and...

ANAB : 19.19 (-3.95%)
AnaptysBio, Inc. (ANAB) Soars 6.2%: Is Further Upside Left in the Stock?

AnaptysBio, Inc. (ANAB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term....

ANAB : 19.19 (-3.95%)
GRTS : 1.7700 (-1.39%)
AnaptysBio Appoints Daniel Faga As Interim Chief Executive Officer

Company to undergo a strategic portfolio review while continuing to execute on the development of its three wholly-owned clinical stage antibody programs ...

ANAB : 19.19 (-3.95%)
AnaptysBio's (ANAB) Acne Study on Imsidolimab Fails to Meet Goal

AnaptysBio's (ANAB) phase II study evaluating imsidolimab for treating moderate-to-severe acne, fails to show improvement over placebo in top-line primary or secondary endpoints. Shares down.

VRTX : 270.84 (+0.88%)
ATHX : 0.1849 (-7.83%)
ANAB : 19.19 (-3.95%)
KLDO : 0.0575 (-1.20%)
AnaptysBio Reports Imsidolimab ACORN Phase 2 Clinical Trial Data in Moderate-to-Severe Acne

Imsidolimab (anti-IL-36R Ab) treatment did not demonstrate improvement over placebo in top-line primary or secondary endpointsAnaptysBio to discontinue...

ANAB : 19.19 (-3.95%)
AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Lags Revenue Estimates

AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -149.56% and 99.42%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

ANAB : 19.19 (-3.95%)
ANIK : 21.60 (+2.71%)
AnaptysBio Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Pipeline Update

Imsidolimab GPP GALLOP Phase 2 16-week data presented at 2021 EADV Congress and Phase 3 GPP GEMINI-1 trial initiatedTop-line data anticipated from ongoing...

ANAB : 19.19 (-3.95%)
Scholar Rock Holding Corporation (SRRK) Reports Q4 Loss, Lags Revenue Estimates

Scholar Rock Holding Corporation (SRRK) delivered earnings and revenue surprises of 6.73% and 4.51%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for...

SRRK : 4.99 (-1.19%)
ANAB : 19.19 (-3.95%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

AnaptysBio, Inc. is a biotechnology company. It involved in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology primarily in the Unites states. AnaptysBio, Inc. is based in San Diego, California.

See More

Key Turning Points

3rd Resistance Point 21.08
2nd Resistance Point 20.62
1st Resistance Point 19.90
Last Price 19.19
1st Support Level 18.72
2nd Support Level 18.26
3rd Support Level 17.54

See More

52-Week High 37.89
Fibonacci 61.8% 30.66
Fibonacci 50% 28.43
Fibonacci 38.2% 26.20
Last Price 19.19
52-Week Low 18.97

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar